Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease

To join this study, you must have bowel cancer that has spread to your liver, and your liver must be the main area affected by the cancer. The cancer in your liver should be measurable on scans. If the cancer has spread outside the liver, it can only be to a very limited extent, like small spots in the lungs or nearby lymph nodes.

You should have already tried and not responded to, or couldn't tolerate, other common chemotherapy drugs for bowel cancer. You also need to be generally well enough to take part in a study like this, as determined by your healthcare team. This study is for people aged 18 and over.

There are some reasons you may not be able to join. For example, if you have a serious liver condition like advanced cirrhosis, or significant heart problems. Your medical team will carefully check all these points to see if this study is suitable and safe for you.

If you decide to take part, you'll be assigned by chance to one of two groups. Two out of three people will receive up to two special treatments where the chemotherapy is given directly to the liver, followed by standard cancer medications. The other group will receive only the standard cancer medications. The standard medications will continue as long as they are working and you are tolerating them well.

Throughout the study, you will have regular clinic visits, usually every two weeks, for check-ups and blood tests. You will also have scans, such as CT or MRI, about every two months to see how the treatment is affecting your cancer. These tests help the doctors monitor your health and the progress of your treatment. The study will continue until your cancer progresses, you experience side effects that are too difficult to manage, or if you decide to stop participating.